Drug Database
TA

tamsulosin (tamsulosin WOWTAB / Harnal D)

✓ Approved

Astellas Pharma · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namestamsulosin WOWTAB, Harnal D
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Astellas Pharma

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedGalen medical journal2026-07-25

Effect of Tamsulosin on Osteopontin Gene Expression in Preventing Ethylene Glycol-Induced Kidney Stone in Male Wistar Rats : Short title: Effect of Tamsulosin on Osteopontin Gene Expression.

Parvizrad Ramin R, Ghorbani Marghamlki Elahe E, Nikfar Somayeh S, Khalili Dermani Sara S

Tamsulosin, an α1-adrenergic receptor antagonist, has been proposed as a potential therapeutic agent against urolithiasis-induced renal damage. However, limited in vivo evidence exists regarding its renoprotective mechanisms. Forty male Wistar rats were randomly allocated into four groups (n=10/group): positive control, negative control (ethylene glycol-induced urolithiasis), prevention (tamsulosin administered simultaneously with ethylene glycol), and treatment (tamsulosin administered after model induction). Biochemical parameters including serum creatinine, urea, uric acid, calcium, and phosphorus were measured using rat-validated commercial kits (Pars Azmun, Iran). Normal ranges were defined based on published reference values. Gene expression was analyzed by qPCR using the 2^-ΔΔCt method. Study design and reporting followed the ARRIVE checklist. At day 30, the prevention group exhibited significantly lower serum creatinine (0.60 ± 0.08 mg/dL) compared to the negative control (0.98 ± 0.12 mg/dL, P0.01). Although urea levels were slightly higher in the prevention group (4.0 ± 0.7 mg/dL) versus the negative control (3.22 ± 0.6 mg/dL), the calculated BUN/creatinine ratio was significantly improved (46.7 vs. 33.0, P0.05). No significant changes were observed in serum calcium or phosphorus. Gene expression analysis showed upregulation of protective markers in the prevention group. In vivo findings on the beneficial effects of tamsulosin on the renal profile in ethylene glycol-induced urolithiasis illustrate its protective effects on the renal system through improvement of creatinine clearance and BUN/creatinine balance. This underscores its probable use as a protective therapeutic agent against renal injury of crystallization origin.

PMID 42499366
Read full article →
PubMedJournal of controlled release : official journal of the Controlled Release Society2026-07-25

Simple hybrid predictive model for point-of-care pharmaceutical tablet disintegration.

Leung Chi Ki CK, Bawuah Prince P, Spiesshofer Nicolas N, Kottlan Andreas A et al.

Ensuring the consistent disintegration performance of immediate-release oral solid dosage (OSD) forms throughout their shelf life is critical for therapeutic efficacy, yet predicting point-of-care performance from manufacturing data remains a significant challenge. Current predictive approaches often rely on empirical correlations or high-dimensional black-box models that lack mechanistic insight and longitudinal validity. To address this, a simple hybrid model that predicts longitudinal disintegration times tdisint,T solely from at-line porosity measurements fat-line is established. The framework is anchored in United States Pharmacopoeia <701> standards to ensure regulatory compliance and reproducibility, while maintaining an architecture that is agnostic to the specific porosity characterisation technique. Utilising a five-year real-time stability dataset with different formulations and tablet geometries, global models are established and demonstrate exceptional predictive accuracy (R2>0.92) across all longitudinal time points. The operating range lies in fat-line∈[0.1,0.3], which is the typical porosity range of pharmaceutical OSDs. The model's longitudinal validity is predicated on the physicochemical stability of the formulation, allowing the model parameters to serve as quantitative indicators in stability assessments. The simplicity and adaptability of this mechanistically grounded model offer a pragmatic path to demonstrating dosage form efficacy at the point-of-care, providing a robust alternative to traditional, destructive end-point testing. By relating at-line structural attributes to long-term performance, this model facilitates Quality by Design in development, seamless technical transfer, and robust real-time release testing. Ultimately, this framework ensures that the rigorously designed quality standards are demonstrably preserved until the moment of patient administration.

PMID 42498232
Read full article →
PubMedJournal of environmental sciences (China)2026-07-25

Microbial activity and hydroxyl radical oxidation combine to induce CO2 release from winter biocrusted soils.

Guo Xing X, Yang Jungang J, Gong Lu L, Zhang Yuanming Y et al.

Soil CO2 release under winter snow in arid regions significantly impacts the carbon balance. Enzymatic decomposition is believed to be the primary driver of CO2 release, however, continuous snow cover promotes the formation of the hydroxyl radical (•OH). Under snow-covered conditions, whether •OH oxidation constitutes an alternative organic matter decomposition pathway to microbial activity, and how these processes interact, remains poorly understood. In this study, we investigated the differences in the CO2 release rates at various depths in biological soil crusts under snow cover and examined the impacts of microbial activity and •OH oxidation on CO2 release. The findings indicate that snow cover has an insulating effect on soil temperature, and that temperature fluctuations decrease with increasing depth. However, this insulating effect did not significantly alter the relative contribution of different soil layers to CO2 release. The crust layer and the 0-5 cm soil layer are the primary zones of CO2 release, while the 5-10 cm layer contributes less. In addition, prolonged infiltration of snowmelt promotes •OH generation, which may play a significant role in regulating CO2 release during winter. Microbial activity primarily influences CO2 production in the surface layer, whereas CO2 emissions from deeper soil are mainly driven by •OH oxidation. This study highlights that under winter conditions when microbial activity is suppressed, both biotic and abiotic processes contribute to CO2 release across different soil depths. Given that snow cover is widespread in terrestrial ecosystems, •OH-mediated CO2 release from deeper soil may represent a previously overlooked carbon emission pathway.

PMID 42498364
Read full article →
PubMedJournal of fish biology2026-07-25

Early life history of the Korean seahorse, Hippocampus haema: Evidence for direct settlement and ontogenetic shifts in snout morphology.

Lee Jaehwan Juan JJ, Kim Jin-Koo JK

Early life-history traits of seahorses are closely linked to juvenile survival, dispersal potential and the onset of substrate attachment; however, detailed stage-resolved descriptions remain limited for many Hippocampus species. This study examined reproductive behaviour and early ontogenetic development of the Korean seahorse, Hippocampus haema, during a 40-day laboratory rearing period. Newborns were released in a relatively advanced skeletal condition, particularly in the caudal skeleton. Skeletal staining showed that the caudal bony plates were already ossified and connected at birth, whereas the trunk plates were still only partially connected. Consistent with this condition, newborns bent the prehensile tail and attached to nearby structures immediately after release, indicating functional competence for substrate attachment at birth and suggesting a very short or indistinct planktonic phase under the observed conditions. Coronet morphology changed markedly during juvenile development, with the anterior coronet spine progressively fusing with the coronet. Morphometric model comparison did not strongly support a continuous power function allometry across measured traits. However, segmented regression identified a significant breakpoint in snout depth at 21.3 mm standard length, after which snout depth increased approximately 2.6-fold more steeply. These findings indicate that H. haema is characterised by advanced caudal skeletal development at birth, immediate tail attachment, dynamic coronet development and a discrete ontogenetic shift in snout depth growth. This stage-resolved description provides baseline information for identifying early developmental stages and interpreting early life history variation in this species.

PMID 42498530
Read full article →
PubMedInternational journal of pharmaceutics2026-07-25

Development of propranolol hydrochloride extended-release lipid matrix tablets for pediatric use.

Broocks Stefanie S, Gebhardt Melanie M, Klein Sandra S

Although solid oral dosage forms are widely used in adult drug therapy, age-appropriate formulations for pediatric patients remain limited. The development of suitable dosage forms is challenged by specific requirements regarding excipient safety, tablet size, and dose flexibility, as well as the need to improve therapy adherence in the context of frequent dosing. This study aimed to develop a pediatric-appropriate extended-release matrix tablet based on lipid matrix formers, with particular attention to the use of safe excipients and the selection of excipients based on sustainability considerations. Lipid-based excipients, selected due to their natural origin and similarity to dietary fats, were investigated and compared with conventional matrix formers. A formulation screening approach was applied to identify promising candidates based on drug release after one hour, followed by further evaluation of manufacturability, tablet hardness, and extended-release performance. In addition, the influence of a physiological pH-gradient, bile salts, and long-term storage on drug release was assessed. The selected formulations showed good manufacturability, uniformity, and sustained drug release. Overall, several lipid-based matrix formulations suitable for pediatric use were identified, providing a promising basis for the development of solid oral extended-release dosage forms for children.

PMID 42497932
Read full article →
PubMedArthroscopy techniques2026-07-25

Anterior Cruciate Ligament Reconstruction Using a Hollow Ligament Advanced Reinforcement System Semitendinosus Autograft Combined With Anterolateral Complex Augmentation Using Gracilis.

Zhu Tianhao T, Huang Changming C, Fan Huaqiang H, Fu Yangpan Y et al.

This technical note describes an alternative surgical technique for anterior cruciate ligament (ACL) reconstruction combined with anterolateral complex (ALC) augmentation. The procedure uses a hollow ligament advanced reinforcement system (LARS), along with semitendinosus and gracilis tendons as grafts. Key surgical steps include arthroscopic exploration, graft preparation, tunnel drilling, and fixation. This technique reduces autologous tendon harvesting, reduces the risk of neurovascular injury, and facilitates immediate restoration of knee rotational stability with early postoperative mobilization. Nonetheless, potential limitations include the possibility of femoral positioning errors and a relatively steep learning curve. This method is particularly suitable for patients with thin autologous tendons, high athletic demands, or those undergoing revision ACL surgery, as it can augment smaller autologous grafts and confer immediate mechanical strength via the structural support of the hollow LARS ligament, thereby helping to maintain knee stability in the early postoperative period.

PMID 42499843
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin